10-Q: Codexis Reports Q2 2026 Results, Revenue Up, Losses Continue

Codexis, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, reporting an increase in product revenue but a continued net loss, alongside a significant decrease in cash and cash equivalents.

Summary

• Codexis, Inc. reported total revenues of $14.9 million for Q2 2026, a slight decrease of 3% year-over-year, driven by a significant drop in R&D revenue offset by a strong increase in product revenue.
• Product revenue grew 79% to $13.2 million in Q2 2026, attributed to higher sales of enzymes for commercial and clinical-stage manufacturing.
• Research and development revenue decreased by 79% to $1.7 million, primarily due to the non-recurrence of significant milestone and licensing revenue recognized in Q2 2025.
• The company reported a net loss of $12.0 million for Q2 2026, an improvement from $13.3 million in the prior year's quarter, with a net loss per share of $0.13.
• Cash and cash equivalents decreased significantly to $27.2 million as of June 30, 2026, down from $50.8 million at the end of 2025.
• The company entered into an underwriting agreement for a public offering of common stock, closing on July 27, 2026, which raised approximately $23.1 million in net proceeds.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to continued net losses, a significant decrease in cash reserves, and a substantial increase in interest and other expenses, despite some revenue growth.

Positives

• Product revenue saw a substantial increase of 79% to $13.2 million in Q2 2026 compared to the same period in 2025.
• Product gross margin improved to 73% in Q2 2026 from 72% in Q2 2025, and 64% in the first six months of 2025 to 73% in the first six months of 2026.
• Net loss decreased by 10% to $12.0 million in Q2 2026 compared to $13.3 million in Q2 2025.
• Net loss for the first six months of 2026 decreased by 39% to $20.7 million compared to $34.0 million in the same period of 2025.
• The company successfully raised approximately $23.1 million in net proceeds from a public offering of common stock in late July 2026.

Negatives

• Total revenues decreased by 3% to $14.9 million in Q2 2026 compared to $15.3 million in Q2 2025.
• Research and development revenue experienced a sharp decline of 79% to $1.7 million in Q2 2026.
• Cash and cash equivalents decreased by approximately 46.5% from $50.8 million at December 31, 2025, to $27.2 million at June 30, 2026.
• Interest and other expense, net, increased by 32% to $1.3 million in Q2 2026 compared to $1.0 million in Q2 2025, primarily due to higher interest on long-term debt.
• The company has a history of net losses, with an accumulated deficit of $627.5 million as of June 30, 2026.

Risks

• The company has a history of net losses and may not achieve or maintain profitability, with significant operating expenses and net losses expected for the foreseeable future.
• The novel and largely unproven nature of the ECO Synthesis manufacturing platform for enzymatic nucleic acid synthesis carries risks of failure to validate performance at scale, demonstrate regulatory acceptance, or overcome other challenges, which could impede customer adoption.
• The company is dependent on a limited number of key customers, and the loss or reduction of business from these customers could materially adversely affect revenues.
• Product supply agreements have finite durations, may not be extended or renewed, and generally do not require customers to purchase specific quantities, increasing revenue unpredictability.
• The demand for products depends on customers' research and development and the clinical and market success of their products, which are subject to numerous uncertainties.
• The company relies on a limited number of third-party contract manufacturers for large-scale production of its enzymes, creating risks of performance issues or interruptions.
• The company's ability to secure additional capital may be necessary if current plans change, and future financings could dilute existing stockholders.
• The company is subject to restrictive covenants in its Loan Agreement with Innovatus, which limit its business and operations.

Future Outlook

The company believes its existing cash and cash equivalents, combined with future product and R&D revenues and expense management, will provide adequate funds for at least the next 12 months. However, additional capital may be needed if plans change, and future financings could involve equity offerings, debt, or collaborations. The company expects to continue incurring significant operating expenses and net losses in the foreseeable future due to ongoing development of its ECO Synthesis platform and expansion of commercial activities.

Management Comments

• The company is actively managing its cash usage and investment of liquid cash to ensure sufficient funds for working capital needs.
• The company believes its existing cash and cash equivalents, combined with future expectations for product revenues, research and development revenue, and expense management will provide adequate funds for planned ongoing operations, capital expenditures and working capital requirements for at least the next 12 months.
• The company may need additional capital if its current plans and assumptions change, and may not be able to raise sufficient additional funds on terms that are favorable, if at all.

Industry Context

StockSavvy.ai notes that Codexis operates in the highly competitive biotechnology and pharmaceutical manufacturing technology sector. The company's focus on enzyme engineering for therapeutics manufacturing, particularly its ECO Synthesis platform for RNAi therapeutics, places it at the intersection of synthetic biology and advanced drug production. The increasing demand for efficient and sustainable manufacturing processes in the biopharmaceutical industry presents both opportunities and challenges, especially given the regulatory hurdles and the rapid pace of technological advancement in this field.

Comparison to Industry Standards

• The company's product gross margin of 73% for the six months ended June 30, 2026, is strong, but direct industry-wide comparisons for specialized enzyme manufacturing are difficult without specific data from competitors like Ginkgo Bioworks, Novozymes, or DuPont's industrial enzyme divisions.
• The net loss of $20.7 million for the first six months of 2026 is substantial, reflecting the high R&D investment typical in the biotech sector, but it is an improvement from the prior year, indicating progress towards potential profitability, a key metric for investors in this capital-intensive industry.
• The significant decrease in cash and cash equivalents to $27.2 million highlights the capital-intensive nature of developing and scaling new manufacturing platforms like ECO Synthesis, a common challenge for early-stage or growth-focused biotech firms.

Legal Proceedings

• The company is not currently a party to any material pending litigation or other material legal proceedings.

Stakeholder Impact

• Shareholders may experience dilution if future capital raises involve equity issuance.
• The company's ability to fund operations and growth may be impacted by its cash position and need for future capital.
• Customers may benefit from improved manufacturing processes for therapeutics through Codexis' enzyme technology.
• Suppliers and contract manufacturers are critical to the company's supply chain, with risks associated with their performance.

Next Steps

• Commence retrofit construction of the ECO GMP Manufacturing Center during the second half of 2026.
• The ECO GMP Manufacturing Center is expected to support customers' early clinical trial supply requirements.
• Continue to expand enzymatic tools and process offerings for the ECO Synthesis platform.
• Evaluate the effects of recently issued accounting pronouncements (ASU No. 2024-03 and ASU 2025-01) on consolidated financial statements.

Key Dates

Recommendation

While product revenue growth is a positive sign, the continued net losses, significant cash burn, and reliance on future capital raises suggest a cautious approach. The improvement in net loss and the successful capital raise are mitigating factors, but the inherent risks in developing novel platforms and the competitive landscape warrant a 'hold' recommendation until sustained profitability and cash flow generation are demonstrated.

Keywords

enzyme technology, biocatalysis, RNAi therapeutics, ECO Synthesis, drug manufacturing, pharmaceutical intermediates, directed evolution, CodeEvolver